|Chennai||Rs. 24470.00 (1.37%)|
|Mumbai||Rs. 24900.00 (0.97%)|
|Delhi||Rs. 24200.00 (1.26%)|
|Kolkata||Rs. 24160.00 (0%)|
|Kerala||Rs. 24000.00 (0.63%)|
|Bangalore||Rs. 23800.00 (0%)|
|Hyderabad||Rs. 24140.00 (1.17%)|
Glaxo SmithKline Pharmaceutical today said it is looking at launching its patented medicine promecta, used in treatment of depleted platelet count, in India by this year-end or early next year.
"We are looking to launch our promecta in the Indian market in the fourth quarter of this year or in the first quarter of next year," GSK Vice President South Asia and Managing Director India Hasit Joshipura told reporters on the sidelines of a function here.
When asked if the company has got drug regulator DCGI nod for launching the medicine here, he said, "We have applied for the regulatory approval but we haven't got it yet. But we hope to get it by the end of this year of early next year."